Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Eur J Immunol ; 52(1): 149-160, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34695227

RESUMEN

During the COVID-19 pandemic, Portugal has experienced three distinct SARS-CoV-2 infection waves. We previously documented the prevalence of SARS-CoV-2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 months later, up to the second week of March 2021, shortly following the third wave, which was one of the most severe in the world, and 2 months following the start of the vaccination campaign. A longitudinal epidemiological study was conducted, with a stratified quota sample of the Portuguese population. Serological testing was performed, including ELISA determination of antibody class and titers. The proportion of seropositives, which was 2.2% in September 2020, rose sharply to 17.3% (95% CI: 15.8-18.8%) in March 2021. Importantly, circulating IgG and IgA antibody levels were very stable 6 months after the initial determination and up to a year after initial infection, indicating long-lasting infection immunity against SARS-CoV-2. Moreover, vaccinated people had higher IgG levels from 3 weeks post-vaccination when compared with previously infected people at the same time post-infection.


Asunto(s)
Anticuerpos Antivirales/inmunología , Prueba Serológica para COVID-19 , COVID-19 , Inmunoglobulina A/inmunología , Inmunoglobulina G/inmunología , SARS-CoV-2/inmunología , Adolescente , Adulto , COVID-19/epidemiología , COVID-19/inmunología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Portugal/epidemiología , Prevalencia , Factores de Tiempo
2.
Emerg Infect Dis ; 27(11): 2878-2881, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34437830

RESUMEN

In September 2020, we tested 13,398 persons in Portugal for antibodies against severe acute respiratory syndrome coronavirus 2 by using a quota sample stratified by age and population density. We found a seroprevalence of 2.2%, 3-4 times larger than the official number of cases at the end of the first wave of the pandemic.


Asunto(s)
COVID-19 , SARS-CoV-2 , Humanos , Pandemias , Portugal/epidemiología , Prevalencia , Estudios Seroepidemiológicos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...